Biotechnology and Genetic Engineering Reviews

Biotechnology and Genetic Engineering Reviews is an annual review title that Taylor & Francis publishes from Abingdon, and for most of its life it was built out of long commissioned reviews rather than primary research, with a 2025 Journal Impact Factor of 2.4.《生物技术与基因工程评论》是 Taylor & Francis 在阿宾登出版的年度综述刊物，大半生涯由长篇约稿综述构成而非原始研究，2025 年期刊影响因子 2.4。

Its first volume is dated 1984 and came from Intercept in Newcastle upon Tyne, and the name has needed no change in the four decades since.第 1 卷标注 1984 年，出自纽卡斯尔的 Intercept，此后四十年刊名无需改动。

Scope

• Industrial enzymology holds a large part of the back catalogue, from L-asparaginase production to engineered microbial factories for hirudin and the protease preparations used across food processing.工业酶学占了旧卷的一大块，从 L-天冬酰胺酶的生产，到用改造过的微生物工厂制造水蛭素，以及食品加工各环节用的蛋白酶制剂。

• Recombinant DNA and genome editing run through the whole set, with CRISPR treated as an evolving toolkit in one review and as an industrial property question in another.重组 DNA 与基因组编辑贯穿全套刊物，CRISPR 在一篇综述里被当作演进中的工具，在另一篇里被当作产业产权问题。

• Medical biotechnology covers engineered cells and gene transfer, taking in CAR T-cell therapy, viral vectors for Alzheimer's disease and the methylation that silences a transgene in mammalian cells.医学生物技术覆盖工程化细胞与基因转移，CAR T 细胞疗法、用于阿尔茨海默病的病毒载体，以及使哺乳动物细胞中转基因沉默的甲基化都在其中。

• Virology has been a standing strength, with reviews of rhabdovirus and vaccinia vaccine platforms, of HIV reservoirs and hepatitis B lymphotropism, and of the non-coding RNAs that viruses exploit.病毒学是长期强项，弹状病毒与痘苗病毒疫苗平台、艾滋病病毒储存库与乙肝病毒嗜淋巴性，以及病毒利用的非编码 RNA 都有综述。

• Plant biotechnology takes in tissue culture and transformation of Brassica crops, iron toxicity and phosphorus deficiency in rice, anthocyanin genetics in cereals and the chemistry of Artemisia annua.植物生物技术收入芸薹属作物的组织培养与转化，也收入水稻的铁毒害与缺磷，以及谷物花青素遗传和黄花蒿的化学。

• Agricultural microbiology appears through engineered probiotics and functional metagenomics for agronomy, along with reviews of the fungal endophytes that live inside plant tissue.农业微生物经改造过的益生菌与面向农学的功能宏基因组学得到呈现，生活在植物组织内部的真菌内生菌也有综述。

• Environmental and industrial biotechnology form a steady block, from microbial fuel cells and immobilised laccase through bioremediation of xenobiotics to zero-waste lignocellulosic refineries.环境与工业生物技术自成一稳块，从微生物燃料电池与固定化漆酶，到异源物质的生物修复与零废弃木质纤维素炼厂。

• Biosensors and bioanalytics get reviews of their own, with immobilised lipase electrodes, liquid biopsy platforms and flux-balance analysis each treated as a technology in its own right.生物传感器与生物分析另有综述，固定化脂肪酶电极、液体活检平台与通量平衡分析各自按一门技术来处理。

• Tissue engineering and regenerative medicine appear through reviews of stem cells on synthetic or biological scaffolds and of the biomaterials chosen for bone regeneration.组织工程与再生医学以综述形式出现，一篇谈合成或生物支架上的干细胞，一篇谈用于骨再生的生物材料选择。

• Bioinformatics and computation are covered as method, from drug discovery pipelines to the in silico strategies assembled against COVID-19 in 2020 and 2021.生物信息学与计算工作按方法学收录，从药物发现流程，到 2020 年与 2021 年为应对新冠而搭建的计算策略。

• Food security and the politics of genetically modified crops enter through regional reviews, one of them a sustained assessment of GMO policy across Africa.粮食安全与转基因作物的政策问题经区域综述进入刊物，其中一篇对非洲各地的转基因政策做了持续评估。

• The review form itself is the house product, and articles run long enough to carry a full reference base instead of reporting a single experiment.综述这一体裁本身就是刊物的产品，文章篇幅足以撑起完整的文献基础，不以报告单项实验为目的。

• Conference material has occasionally been folded in, and volume 34 carried the proceedings of a virology meeting held at the University of Alberta in June 2017.会议材料偶尔并入，第 34 卷收录了 2017 年 6 月在阿尔伯塔大学召开的一次病毒学会议的报告。

• The last full volume moved away from that pattern, and most of what it printed were short primary studies on clinical material rather than reviews of a field.最后一个完整卷离了这条路数，印出的多是围绕临床材料的短篇原始研究，而不是某一领域的综述。

History

• Volume 1 is dated 1984, and the National Library of Medicine records Newcastle upon Tyne as the place of publication, with Intercept named as the original publisher.第 1 卷标注 1984 年，美国国家医学图书馆记下的出版地是纽卡斯尔，原出版方记为 Intercept。

• Those early volumes were hardback annuals, and the front matter of volume 2 carries a preface while volume 16 opens with an editor's foreword.早期各卷是精装年刊，第 2 卷卷首有前言，第 16 卷以编者序开篇。

• Ownership moved to Taylor & Francis, whose imprint is now recorded at Abingdon, and the National Library's record gives 2014 as the point where the current address begins.刊物后来归入 Taylor & Francis，现记录的出版地是阿宾登，美国国家医学图书馆把现行地址的起点定在 2014 年。

• Two numbers belong to the title, the print 0264-8725 and the electronic 2046-5556, and Crossref files both under the same record.刊物有两个刊号，印刷本 0264-8725 与电子本 2046-5556，Crossref 把它们记在同一份档案下。

• One volume a year was the pattern, yet the sequence is not perfectly annual, since volume 27 is dated 2010 and volume 28 only 2012.一年一卷是常例，序列却不完全按年，第 27 卷标 2010 年，第 28 卷要到 2012 年。

• Some years produced a single issue and others a pair, and volumes 31 and 32 carried their two parts bound together as issues 1-2.有的年份只出一期，有的年份出两期，第 31 卷与第 32 卷把两部分合编为 1-2 期。

• Volumes 33 to 38 settled into two issues each, holding between five and fifteen review articles per volume through the years from 2017 to 2022.第 33 卷到第 38 卷稳定为每卷两期，2017 年至 2022 年间每卷收五到十五篇综述。

• Volume 34 broke that shape once, carrying the proceedings of the Alberta Virology Conference held at the University of Alberta on 1 and 2 June 2017.第 34 卷破例一次，收录了 2017 年 6 月 1 日至 2 日在阿尔伯塔大学举行的病毒学会议报告。

• Volume 39, dated 2022 and 2023, held 59 items, and volume 40 then took 236 across four numbered issues, most of them dated to 2023.第 39 卷跨 2022 年与 2023 年，收 59 篇，第 40 卷随后在四个编号期里收下 236 篇，多数标 2023 年。

• Nothing dated 2024 or later appears in the Crossref record for either ISSN, and the publisher's table of contents ends with papers dated 30 May 2023.两个刊号的 Crossref 记录里都没有 2024 年及以后的内容，出版方目录止于 2023 年 5 月 30 日的文章。

• MEDLINE coverage ends at volume 40, issue 4, dated 2024, and the National Library of Medicine has recorded nothing after that issue.MEDLINE 的收录止于 2024 年的第 40 卷第 4 期，美国国家医学图书馆在该期之后没有新记录。

• Index Medicus listed the title from the first volume, which is why a 1980s review series ended up in a medical index at all.Index Medicus 从第 1 卷起就收录本刊，一份 1980 年代起步的综述丛书因此进了医学索引。

• The 2025 Journal Citation Reports give a Journal Impact Factor of 2.4 and a five-year figure of 3.1, with 1635 citations counted and a cited half-life of 3.4 years.2025 年期刊引证报告给出影响因子 2.4 与五年值 3.1，计入被引 1635 次，被引半衰期 3.4 年。

• The same report places it in the third quartile in both categories, at 122 of 180 in biotechnology and applied microbiology and 107 of 192 in genetics and heredity.同一份报告把刊物在两个类目里都列在第三四分位，生物技术与应用微生物学 180 种中列第 122，遗传学与遗传 192 种中列第 107。

• Four annual figures trace a sharp rise and a fall, 4.2 in 2022, 6.5 in 2023, 1.9 in 2024 and 2.4 in 2025, while gold open access accounts for 1.06 per cent of output.四个年度数字画出一条陡升陡降的线，2022 年 4.2，2023 年 6.5，2024 年 1.9，2025 年 2.4，金色开放获取占发文量的 1.06%。

Editors

• Each volume has been assembled by an editor or a small group, and specials name them in the article itself, as the virology proceedings named Guido van Marle and Trushar R. Patel.每卷由一位或一小组编辑编成，特辑会在文章里具名，病毒学会议报告就写明由 Guido van Marle 与 Trushar R. Patel 编辑。

• The board has been printed and deposited as a citable item at least twice, once in volume 30 in 2014 and once in volume 32 two years later.编委会名单至少两次按可引条目印出并登记，一次是 2014 年第 30 卷，一次是两年后的第 32 卷。

• Editorial correspondence is routed through the publisher's office at Abingdon, and the journal's page on the Taylor & Francis platform carries the submission route.编辑往来经阿宾登的出版社办公室转达，投稿路径写在该社平台上本刊的页面里。

• Commissioning rather than open submission shaped the early volumes, where neighbouring topics were ordered into a single book-length set each year.早期各卷靠组稿而非自由来稿成形，每年把相邻题目编排成一部书那样的成套文章。

• Reviews are refereed even though the authors are invited, since the series sits in Science Citation Index Expanded and has to meet its editorial criteria.综述虽为约稿仍经评审，这套丛书在 Science Citation Index Expanded 之内，须满足其编选标准。

• Special material gets a guest editor with a named institution, which is how a university conference became a citable part of an annual volume.特辑另请挂靠具名机构的客座编辑主持，一场大学会议因此成为年刊里可引的一部分。

• Length is left to the author, and the resulting articles run from a focused twenty pages to surveys that fill most of an issue with their reference lists alone.篇幅交给作者决定，成稿从二十页左右的专题，到参考文献就占去大半期篇幅的通览都有。

• Ahead-of-print scheduling was in use by the end, since papers dated through 2022 were already assigned to volume 40 before that volume closed.末期采用先上线后排期的做法，2022 年上线的文章在第 40 卷合卷之前就已编入该卷。

• Two corrections were issued in 2023 against papers from the preceding volume, both deposited with a DOI and linked to the article they correct.2023 年针对上一卷的文章登出两条更正，两条都带 DOI，并与被更正的原文相互链接。

• The arrival of large numbers of short clinical papers in volume 40 changed what the editorial process had to handle, and the volume simply absorbed them.第 40 卷涌进大批短篇临床论文，编辑流程要处理的稿件形态随之改变，卷内照单收下。